Reduced thalamic F-flurodeoxyglucose retention in adults with neurofibromatosis type 1

Nuclear Medicine Communications

Volumn 29, Issue 1, 2008, Pages 17-26

  Buchert, Ralph ^a   von Borczyskowski, Daniel ^a   Wilke, Florian ^a   Gronowsky, Michael ^a   Friedrich, Reinhard E ^a   Brenner, Winfried ^a   Mester, Janos ^b   Clausen, Malte ^b   Mautner, Victor F ^b  

^a Departments of Nuclear Medicine   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cerebral glucose metabolism; Neurofibromatosis type1; Positron emission tomography; Statistical parametric mapping

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROFIBROMATOSIS; SCINTISCANNING; THALAMUS; ANALYSIS OF COVARIANCE; BRAIN FUNCTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MAJOR CLINICAL STUDY; NERVE SHEATH TUMOR;

ADOLESCENT; ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; RADIOPHARMACEUTICALS; THALAMUS;

EID: 39149131398     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1bbf5     Document Type: Article

References (41)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89:1-6.
2. Petrak B. Neurofibromatosis von Recklinghausen type 1 - current knowledge. Cesk Slov Neurol Neurochir 2004; 67:315-320.
3. North KN, Riccardi V, SamangoSprouse C, Ferner R, Moore B, Legius E, et al. Cognitive function and academic performance in neurofibromatosis 1: Consensus statement from the NF1 cognitive disorders task force. Neurology 1997; 48:1121-1127.
4. North K. Neurofibromatosis type 1. Am J Med Genet 2000; 97:119-127.
5. North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol 2002; 17:605-612; discussion 627-629, 646-651.
6. Kaplan AM, Chen K, Lawson MA, Wodrich DL, Bonstelle CT, Reiman EM. Positron emission tomography in children with neurofibromatosis-1. J Child Neurol 1997; 12:499-506.
7. 18F]-2-fluoro-2-deoxy-D-glucose and PET. J Neurol Neurosurg Psychiatry 1994; 57:1479-1483.
8. Riccardi VM, Eichner JE. Neurofibromatosis. Phenotype, natural history and pathogenesis. Baltimore: Johns Hopkins University Press; 1986.
9. Zoller ME, Rembeck B, Backman L. Neuropsychological deficits in adults with neurofibromatosis type 1. Acta Neurol Scand 1997; 95:225-232.
10. Hyman SL, Gill DS, Shores EA, Steinberg A, Joy P, Gibikote SV, et al. Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 2003; 60:1139-1145.
11. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis. Cancer Res 2002; 62:1573-1577.
12. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006; 33:428-432.
13. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51-57.
14. Van Es S, North KN, McHugh K, De Silva M. MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 1996; 26:478-487.
15. Ferner RE, Chaudhuri R, Bingham J, Cox T, Hughes RA. MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993; 56:492-495.
16. Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J. Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology 2003; 61:1725-1728.
17. Goh WH, Khong PL, Leung CS, Wong VC. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. J Child Neurol 2004; 19:853-858.
18. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150:885-890.
19. Krause KH, Krause J, Trott GE. Hyperkinetic syndrome (attention deficit/hyperactivity disorder) in adulthood. Nervenarzt 1998; 69:543-556.
20. Brown TE. Brown attention-deficit disorder scales, manual. San Antonio: Harcourt Brace and Company; 1996.
21. Achenbach TM. Manual for the child behavior checklist/4-18 and 1991 profile. Burlington: University of Vermont, Department of Psychiatry; 1991.
22. Elternfragebogen über das Verhalten von Kindern und Jugendlichen; deutsche Bearbeitung der Child Behavior Checklist (CBCL/4-18). Köln: Arbeitsgruppe Kinder-, Jugend- und Familiendiagnostik: Arbeitsgruppe DeutscheChild Behavior Checklist, 1993.
23. Leark, RA. Clinical interpretation of the test of variables of attention. In: Golden C, editor. Interpretation of psychological tests. New York: Plenum; 2000.
24. Kaneko K, Kuwabara Y, Sasaki M, Koga H, Abe K, Baba S, et al. Validation of quantitative accuracy of the post-injection transmission-based and transmissionless attenuation correction techniques in neurological FDG-PET. Nucl Med Commun 2004; 25:1095-1102.
25. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15:273-289.
26. Van Bogaert P, Wikler D, Damhaut P, Szliwowski HB, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. Neuroimage 1998; 8:62-68.
27. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 1996; 46:1660-1668.
28. Wang PY, Kaufmann WE, Koth CW, Denckla MB, Barker PB. Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging. Ann Neurol 2000; 47:477-484.
29. Eastwood JD, Fiorella DJ, MacFall JF, Delong DM, Provenzale JM, Greenwood RS. Increased brain apparent diffusion coefficient in children with neurofibromatosis type 1. Radiology 2001; 219:354-358.
30. Tognini G, Ferrozzi F, Garlaschi G, Piazza P, Patti A, Virdis R, et al. Brain apparent diffusion coefficient evaluation in pediatric patients with neurofibromatosis type 1. J Comput Assist Tomogr 2005; 29:298-304.
31. Alkan A, Sigirci A, Kutlu R, Ozcan H, Erdem G, Aslan M, et al. Neurofibromatosis type 1: diffusion weighted imaging findings of brain. Eur J Radiol 2005; 56:229-234.
32. Kadekaro M, Crane AM, Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci U S A 1985; 82:6010-6013.
33. Chapman CA, Waber DP, Bassett N, Urion DK, Korf BR. Neurobehavioral profiles of children with neurofibromatosis 1 referred for learning disabilities are sex-specific. Am J Med Genet 1996; 67:127-132.
34. Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996; 138:125-133.
35. Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study. Neuroimage 1999; 10:397-407.
36. Buchert R, Berding G, Wilke F, Martin B, von Borczyskowski D, Mester J, et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging 2006; 33:1073-1083.
37. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388.
38. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238:E69-82.
39. Ishii K, Higashi Y, Tabata M, Miyaishi M, Mizutani T, Sasaki M. Necessity of a uniform start for scanning after FDG injection in brain PET study. Ann Nucl Med 2006; 20:329-331.
40. Kessler RM, Ellis JR Jr, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984; 8:514-522.
41. Moore BD 3rd, Slopis JM, Jackson EF, De Winter AE, Leeds NE. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000; 54:914-920.